Unibest

Pharmaceutical intermediates

Fezolinetant Intermediates

6 pharmaceutical intermediates for Fezolinetant. Indication: Vasomotor Symptoms; Hot Flashes.

提交项目All intermediates

About Fezolinetant

Originator
Ogeda SA
Indication
Vasomotor Symptoms; Hot Flashes
Approved Date
05/12/2023
NCE Patent
05/12/2028
DS/DP
04/04/2031

Available intermediates

6 intermediates currently listed for Fezolinetant. Request specifications, documentation or a quotation for any item below.

Fezolinetant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Methyl-1,2,4-thiadiazole-5-carbohydrazide1375066-73-1//
(R)-3-Methylpiperazin-2-one922178-61-8//
(R)-4-(2,4-diMethoxybenzyl)-3-Methylpiperazin-2-one1383146-20-0//
3-Methyl-piperazin-2-one23936-11-0//
5-bromo-3-methyl-1,2,4-thiadiazole54681-68-4//
3-Methyl-[1,2,4]thiadiazole-5-carboxylic acid ethyl ester76162-56-6//

Other programs under F

FebuxostatFexuprazan HClFilgotinib MaleateFinerenoneFluralanerFostamatinib disodium hexahydrateFruquintinibFutibatinib

Building toward Fezolinetant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →